Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted EBT Margin of 76.25% for Q1 2026, down 19.14% on a QoQ basis from 64.0% in Q4 2025, and up 8420.0% year-over-year from 0.89% in Q1 2025.
Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' EBT Margin history runs 15 years deep, the most recent figure standing at 76.25% for Q1 2026.
- Quarterly EBT Margin rose 8420.0% year-over-year to 76.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.42% (up 6399.0% YoY) and the FY2025 annual result came in at 127.9%, up 4625.0% from the prior year.
- EBT Margin was 76.25% for Q1 2026 at Enanta Pharmaceuticals, down from 64.0% in the prior quarter.
- Across five years, EBT Margin topped out at 64.0% in Q4 2025 and bottomed at 211.37% in Q1 2023.
- A 5-year average of 147.55% and a median of 155.91% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin tumbled 6597 bps — and 2026, when it jumped 8420 bps.
- Enanta Pharmaceuticals' EBT Margin stood at 123.04% in 2022, then slumped by 54 bps to 189.02% in 2023, then grew by 29 bps to 133.89% in 2024, then jumped by 52 bps to 64.0% in 2025, then dropped by 19 bps to 76.25% in 2026.
- Business Quant data shows ENTA's EBT Margin at 76.25% in Q1 2026, 64.0% in Q4 2025, and 123.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -76.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.25% |
| Dec 31, 2025 | -64.00% |
| Sep 30, 2025 | -123.42% |
| Jun 30, 2025 | -99.52% |
| Mar 31, 2025 | -160.45% |
| Dec 31, 2024 | -133.89% |
| Sep 30, 2024 | -199.81% |
| Jun 30, 2024 | -128.28% |
| Mar 31, 2024 | -184.82% |
| Dec 31, 2023 | -189.02% |
| Sep 30, 2023 | -155.91% |
| Jun 30, 2023 | -184.44% |
| Mar 31, 2023 | -211.37% |
| Dec 31, 2022 | -123.04% |
| Sep 30, 2022 | -129.62% |
| Jun 30, 2022 | -165.03% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -109.05% |
| Sep 30, 2021 | -141.65% |
| Jun 30, 2021 | -154.50% |